Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.
| Ticker |
PACB
|
| CIK | 0001299130 |
| SIC | 3826 |
| Sector | Manufacturing |
| Industry Category | Measuring And Control Equipment |
| Industry Group | Lab Analytical Instruments |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to KnowThe latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close. Here's Why You Should Add PacBio Stock to Your Portfolio NowPACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth. Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should KnowPacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Pacific Biosciences Targets Profitability by 2027 With Record Consumables RevenuePacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, […] An Intrinsic Calculation For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Suggests It's 35% UndervaluedKey Insights The projected fair value for Pacific Biosciences of California is US$2.00 based on 2 Stage Free Cash Flow... |